- Home
- / Lysogene
Lysogene
Total Funding
$22 M
Revenue
€3.7 M
FY, 2021
Lysogene Summary
Company Summary
- Overview
- Lysogene is a company that provides research and clinical development of gene therapy for neurodegenerative disorders. It offers AAV vectors for safely delivering genetic material to the central nervous system.
- Type
- Private
- Status
- Active
- Founded
- 2009
- HQ
- Neuilly-sur-Seine, FR | view all locations
- Website
- http://www.lysogene.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Karen Pignet-Aiach, Founder, Chair and Chief Executive Officer
Marie Deneux, Chief Regulatory Officer
Marie Trad, Chief Clinical Officer
LocationsView all
2 locations detected
Neuilly-sur-Seine, Île-de-France HQ
France
18 Rue Jacques Dulud
Cambridge, MA
United States
2 First St 18th floor
Lysogene Financials
Summary Financials
- Revenue (H1, 2022)
- €8.4M
- Gross profit (H1, 2022)
- €9.0M
- Net income (H1, 2022)
- €703.0K
- Cash (H1, 2022)
- €7.7M
- EBIT (H1, 2022)
- €905.0K